Stay updated with breaking news from Treat Solid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HanchorBio Received IND Approval of HCB101 Multi-Regional Clinical Trial By Taiwan FDA TAIPEI & SAN FRANCISCO, July 24, 2023 (Newswire.com) - HanchorBio Inc., a global clinical-stage biotechnology company...
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies HanchorBio Received IND Clearance of HCB101 Multi-regional Clinical Trial By US FDA TAIPEI, TAIWAN and SAN FRANCISCO, ...
New studies highlight CAR-T therapy’s success in treating acute lymphoblastic leukemia and lymphoma.
Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicine...
Published: May 05, 2021 Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making tremendous progress towards discovering, developing, and manufacturing nov...